One of the most relevant goals of the musculoskeletal care in hemophilia is to prevent intraarticular bleeding. In the past, usual clinical practice allowed for a tacit, moderate degree of tolerance for sporadic intraarticular hemorrhages, based on the clinical observation that joints were able to tolerate an infrequent bleed with little or no harm. However, increasing knowledge on the pathophysiology of hemarthrosis in vitro and in vivo, as well as in clinical experiments, indicates that we need to move towards a more stringent policy with regards to the prevention of occasional and subclinical intraarticular hemorrhages [1-3].